These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 24029000)

  • 21. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
    Hsia EC; Schluger N; Cush JJ; Chaisson RE; Matteson EL; Xu S; Beutler A; Doyle MK; Hsu B; Rahman MU
    Arthritis Rheum; 2012 Jul; 64(7):2068-77. PubMed ID: 22238071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
    Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
    J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.
    Borekci S; Atahan E; Demir Yilmaz D; Mazıcan N; Duman B; Ozguler Y; Musellim B; Hamuryudan V; Ongen G
    Respiration; 2015; 90(3):191-8. PubMed ID: 26137891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases.
    Yang JY; Jo KW; Hong S; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Park SH; Shim TS
    Infect Dis (Lond); 2016 Apr; 48(4):293-298. PubMed ID: 26667845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
    Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
    J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists.
    Baričević D; Popović Grle S; Morović Vergles J; Čuković Čavka S; Jakopović M; Redžepi G; Boras Z; Baričević M; Samaržija M
    Acta Clin Croat; 2017 Jun; 56(2):203-209. PubMed ID: 29485786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.